Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis  by Tanaka, Nobuyuki et al.
Priority Focus – Urothelial Cancer
Editorial by Brant Inman and Kae Jack Tay on pp. 64–65 of this issue
Impact of Combined Use of Blood-based Inflammatory Markers
on Patients with Upper Tract Urothelial Carcinoma Following
Radical Nephroureterectomy: Proposal of a Cumulative Marker
Score as a Novel Predictive Tool for Prognosis
Nobuyuki Tanaka a, Eiji Kikuchi a,*, Kent Kanao a, Kazuhiro Matsumoto a,b, Suguru Shirotake a,
Yasumasa Miyazaki a, Hiroaki Kobayashi a,c, Gou Kaneko a,d, Masayuki Hagiwara a,e,
Hiroki Ide a,f, Jun Obata a, Katsura Hoshino a, Nozomi Hayakawa a,b, Takeo Kosaka a,g,
Satoshi Hara d, Ken Nakagawa e, Masahiro Jinzaki h, Mototsugu Oya a
aDepartment of Urology, Keio University School of Medicine, Tokyo, Japan; bDepartment of Urology, Saiseikai Central Hospital, Tokyo, Japan; cDepartment of
Urology, Kyosai Tachikawa Hospital, Tokyo, Japan; dDepartment of Urology, Kawasaki City Hospital, Tokyo, Japan; eDepartment of Urology, Ichikawa
General Hospital, Tokyo Dental College, Ichikawa, Japan; fDepartment of Urology, Inagi City Hospital, Tokyo, Japan; gDepartment of Urology, Irumagawa
Hospital, Saitama, Japan; hDepartment of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan
E U R O P E A N U R O L O G Y F O C U S 1 ( 2 0 1 5 ) 5 4 – 6 3
avai la ble at www.sciencedirect .com
journal homepage: www.europeanurology.com
Article info
Article history:
Accepted February 4, 2015
Associate Editor:
Gianluca Giannarini
Keywords:
Urothelial carcinoma
Upper urinary tract
C-reactive protein
Neutrophil-to-lymphocyte ratio
Fibrinogen
Outcome
Prognosis
Marker score
Abstract
Background: Previous studies showed the prognostic impact of preoperative levels of neutrophil-to-
lymphocyte ratio (NLR), plasma fibrinogen, and serum C-reactive protein (CRP) in surgically treated
upper tract urothelial carcinoma; however, few papers have discussed the proper use of these indices.
Objective: To investigate whether combinations of these three markers, as a cumulative marker score
(CMS), improve the accuracy of prognostic models following radical nephroureterectomy (RNU).
Design, setting, and participants: A total of 394 patients from multiple institutions were included.
Median follow-up was 30 mo.
Intervention: All patients underwent RNU without neoadjuvant chemotherapy.
Outcome measurements and statistical analysis: Associated outcomes were assessed using mul-
tivariate analysis. The CMS was deﬁned as the number of elevated levels of preoperative NLR,
plasma ﬁbrinogen, and serum CRP.
Results and limitations: Multivariate analyses revealed that an increasing CMS was independently
associated with high rates of disease recurrence, cancer-speciﬁc mortality, and all-cause mortality
following RNU. Addition of the CMS to a model that included standard clinicopathologic predictors
signiﬁcantly improved predictive accuracy by 2.7% for disease recurrence, 3.9% for cancer-speciﬁc
mortality, and 4.0% for all-cause mortality, which were the highest among other prognostic models
using each marker alone or combinations of two. The study is limited by its retrospective nature.
Conclusions: Although the use of each inﬂammatory marker alone may be as predictive as
clinicopathologic indices for prognosis, combinations like CMS can provide more accurate prog-
nostic models following RNU.
Patient summary: Elevation of blood-based inﬂammatory markers may be useful for predicting
prognosis because of their low cost and accessibility. Among blood-based indices, we examined
the efﬁcacy of preoperative neutrophil-to-lymphocyte ratio, plasma ﬁbrinogen, and serum C-reactive
protein levels. Although use of each marker alone provides additional prognostic information,
the combination of all three markers would be more predictive than any single marker or combina-
tions of two.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The prognosis of upper tract urothelial carcinoma (UTUC)
remains poor due to a high rate of disease relapse after
resection [1–4]. Radical nephroureterectomy (RNU) is the
gold standard for the treatment of nonmetastatic UTUCs;
however, the 5-yr disease-specific survival rate is <50%
for pT2–3 tumors and <10% for pT4 tumors [1]. To predict
UTUC outcomes, many researchers have attempted to
identify potent biomarkers using human tissue and blood
samples [1,5,6], although the vast majority of markers have
not yet been applied in clinical practice. In this regard, a
growing body of evidence suggests the efficacy of systemic
inflammatory markers from blood samples for predicting
patient prognosis and pathologic profiles in UTUC [7–12],
and these biomarkers may become useful because of their
low cost and easy accessibility.
The associations between the involvement of systemic
inflammation and cancer development are now evident.
Tumor recruits endothelial cells, fibroblasts, and inflamma-
tory cells into the tumor bed and then shapes its unique
stroma, suggesting that the elevation of systemic inflam-
matory markers may reflect the development of anTable 1 – Association of baseline clinicopathologic characteristics and
fibrinogen, and serum C-reactive protein in 394 patients treated with 
Eleva
NLR, n (%) Pl
Characteristic All patients
(n = 394), n (%)
Elevated
(n = 108)
Nonelevated
(n = 286)
p value El
(n
Age at RNU
70 yr 205 (52.0) 46 (42.6) 159 (55.6) 5
>70 yr 189 (48.0) 62 (57.4) 127 (44.4) 0.021 6
Sex
Male 289 (73.4) 77 (71.3) 212 (74.1) 8
Female 105 (26.6) 31 (28.7) 74 (25.9) 0.571 3
Tumor location
Renal pelvis 232 (58.9) 64 (59.3) 168 (58.7) 7
Ureter 162 (41.1) 44 (40.7) 118 (41.3) 0.926 4
Tumor grade
G1/2 128 (32.5) 27 (25.0) 101 (35.3) 3
G3 266 (67.5) 81 (75.0) 185 (64.7) 0.051 8
Pathologic T stage
pTa-1 125 (31.7) 24 (22.2) 101 (35.3) 3
pT2 57 (14.5) 16 (14.8) 41 (14.3) 1
pT3 201 (51.0) 63 (58.3) 138 (48.3) 6
pT4 11 (2.8) 5 (4.6) 6 (2.1) 0.055 
Lymphovascular invasion
Negative 224 (56.9) 59 (54.6) 165 (57.7) 5
Positive 170 (43.1) 49 (45.4) 121 (42.3) 0.584 6
Concomitant carcinoma in situ
Negative 320 (81.2) 95 (88.0) 225 (78.7) 9
Positive 74 (18.8) 13 (12.0) 61 (21.3) 0.035 2
Lymph node involvement
pNx 357 (90.6) 96 (88.9) 261 (91.3) 10
pN0 8 (2.0) 2 (1.9) 6 (2.1) 
pN+ 29 (7.4) 10 (9.3) 19 (6.6) 0.670 1
Adjuvant chemotherapy
No 306 (77.7) 84 (77.8) 222 (77.6) 8
Yes 88 (22.3) 24 (22.2) 64 (22.4) 0.974 3
CRP = C-reactive protein; NLR = neutrophil-to-lymphocyte ratio; RNU = radical neinflammation-associated microenvironment in tumors
[13–16]. In UTUC, we and others reported the prognostic
value of typical preoperative inflammatory markers such as
neutrophil-to-lymphocyte ratio (NLR), plasma fibrinogen,
and serum level of C-reactive protein (CRP) in patients
following RNU [7–12].
In the present study, we hypothesize that combinations
of these markers would provide more accurate prognostic
models than a single marker. The aim of this study was to
determine the associations of preoperative NLR, plasma
fibrinogen, and CRP with clinicopathologic features and to
develop multivariate models for prognosis based on each
inflammatory marker alone or in combination.
2. Patients and methods
After institutional review board approval, a total of seven Japanese
institutions—Keio University Hospital and six afﬁliated institutions—
provided data on 457 patients who underwent open or laparoscopic RNU
for localized UTUC between 1995 and 2011. We excluded patients with a
history of muscle-invasive urothelial carcinoma (UC) of the urinary
bladder and those who received neoadjuvant chemotherapies. After
excluding patients without a full set of blood data and those with active
infection accompanied by fever (>38 8C), the presence of hematological elevation of preoperative neutrophil-to-lymphocyte ratio, plasma
radical nephroureterectomy
tion of preoperative marker levels
asma ﬁbrinogen, n (%) Serum CRP, n (%)
evated
 = 117)
Nonelevated
(n = 277)
p value Elevated
(n = 93)
Nonelevated
(n = 301)
p value
7 (48.7) 148 (53.4) 46 (49.5) 159 (52.8)
0 (51.3) 129 (46.6) 0.392 47 (50.5) 142 (47.2) 0.571
4 (71.8) 205 (74.0) 68 (73.1) 221 (73.4)
3 (28.2) 72 (26.0) 0.650 25 (26.9) 80 (26.6) 0.954
0 (59.8) 162 (58.5) 53 (57.0) 179 (59.5)
7 (40.2) 115 (41.5) 0.804 40 (43.0) 122 (40.5) 0.671
1 (26.5) 97 (35.0) 24 (25.8) 104 (34.6)
6 (73.5) 180 (65.0) 0.099 69 (74.2) 197 (65.4) 0.116
0 (25.6) 95 (34.3) 24 (25.8) 101 (33.6)
1 (9.4) 46 (16.6) 12 (12.9) 45 (15.0)
9 (59.0) 132 (47.7) 51 (54.8) 150 (49.8)
7 (6.0) 4 (1.4) 0.005 6 (6.5) 5 (1.7) 0.052
7 (48.7) 167 (60.3) 40 (43.0) 184 (61.1)
0 (51.3) 110 (39.7) 0.034 53 (57.0) 117 (38.9) 0.002
3 (79.5) 227 (81.9) 74 (79.6) 246 (81.7)
4 (20.5) 50 (18.1) 0.567 19 (20.4) 55 (18.3) 0.641
3 (88.0) 254 (91.7) 80 (86.0) 277 (92.0)
4 (3.4) 4 (1.4) 4 (4.3) 4 (1.3)
0 (8.5) 19 (6.9) 0.364 9 (9.7) 20 (6.6) 0.119
0 (68.4) 226 (81.6) 67 (72.0) 239 (79.4)
7 (31.6) 51 (18.4) 0.004 26 (28.0) 62 (20.6) 0.136
phroureterectomy.
Fig. 1 – (A) Recurrence-free and (B) cancer-specific survival rates in
394 patients who underwent radical nephroureterectomy according to
the cumulative marker score.
CMS = cumulative marker score.
E U R O P E A N U R O L O G Y F O C U S 1 ( 2 0 1 5 ) 5 4 – 6 356disorders, chronic inﬂammatory or autoimmune diseases, or prior steroid
therapy, the remaining 394 patients were assessed in further analyses. The
median follow-up of the entire cohort was 30 mo (interquartile range
[IQR]: 15–63 mo).
RNU was performed according to the standard criteria, that is,
extrafascial dissection of the kidney with the entire length of the ureter
and an adjacent segment of the bladder cuff. Surgical specimens were
evaluated at each institution. All specimens were histologically
conﬁrmed to be UC. No patient underwent endoscopic resection
prior to RNU. Dissection of regional lymph nodes was performed in
patients with nodes that were found to be enlarged in a preoperative
evaluation or in those who were suspected of having enlarged nodes at
intraoperative inspection. Indeed, 37 patients underwent lymph node
dissection at the time of RNU. Adjuvant chemotherapy following RNU
was administered to 88 patients.
Tumors were staged according to the 2002 American Joint Committee
on Cancer and Union for International Cancer Control TNM classiﬁcation
and graded according to the 1973 World Health Organization classiﬁca-
tion. Lymphovascular invasion (LVI) was deﬁned as the presence of tumor
cells within an endothelium-lined space without underlying muscular
walls. The presence of concomitant carcinoma in situ (CIS) was assessed in
every representative section. Tumor location was divided into two areas,
the renal pelvis or the ureter, based on the location of the dominant lesion.
The assessment of preoperative blood data was performed just
before any of the manipulations, such as retrograde pyelography and/or
ureteroscopic evaluation with tumor biopsy, whereas RNU was generally
performed within 1 mo following manipulation. NLR was deﬁned as the
absolute neutrophil count divided by the absolute lymphocyte count, and
patients with NLR >3.0 were deﬁned as having elevated NLR [8,9]. Blood
data concerning plasma ﬁbrinogen levels were determined by the Clauss
method, and plasma ﬁbrinogen levels 390 mg/dl were deﬁned as
elevated [11,17]. In this study, patients with serum CRP levels >0.5 mg/dl
were deﬁned as having elevated CRP [12]. The cumulative marker score
(CMS) was deﬁned as the number of elevated preoperative levels of
NLR, plasma ﬁbrinogen, and serum CRP and divided into four groups
(0, 1, 2, and 3).
Patients were generally followed every 3–4 mo for 2 yr following
RNU, every 6 mo for the next 3 yr, and then every 6–12 mo thereafter.
Follow-up consisted of history, physical examination, routine blood
work, urinary cytology, chest radiography, and cystoscopic evaluation of
the urinary bladder. Radiographic evaluations of computed tomography
(CT), magnetic resonance imaging, and/or excretory urograms were
performed every 6 mo for the ﬁrst 5 yr and annually thereafter. Elective
bone scans and chest CT were performed when clinically indicated.
Disease recurrence was deﬁned as any documented ﬁrst relapse by
radiography- or pathology-proven failure in nonbladder lesions, such as
the operative site, regional lymph nodes, or distant metastasis. The
occurrence of urothelial carcinoma in the bladder or contralateral upper
tract was not coded as disease recurrence. The cause of death was
determined by the attending physicians, by chart reviews corroborated by
death certiﬁcates, or by death certiﬁcates alone at each institution. To
reduce bias in attribution of the cause of death, only patients who had UC
listed on the death certiﬁcate were considered to have died of UTUC for this
study [18]. All patients who were coded as dead of cancer had previous
disease recurrence.
2.1. Statistical analysis
The variables of different groups were compared using the chi-square
test or the Mann-Whitney U test, as appropriate. Spearman rank
correlation coefﬁcient was used to compare continuous variables.
Survival curves were estimated using the Kaplan-Meier method, with
the log-rank test used to assess signiﬁcance. Univariate and multivari-
ate Cox regression models were used to evaluate time to diseaserecurrence and cancer-speciﬁc and all-cause mortality. The predictive
accuracy of the multivariate models was estimated by the area under
the receiver operating characteristic curve. Changes in predictive
accuracy were quantiﬁed with the Harrell concordance index [19,20],
and area under the curve internal validation was performed using
200 bootstrap resamples. Predictive accuracy estimates are expressed
as percentages and were compared using the Mantel-Haenszel test.
Differences among groups were regarded as signiﬁcant when
p < 0.05. Statistical analyses were performed with the R Statistical
Language version 2.9 (R Foundation, Vienna, Austria) and SPSS version
22.0 (IBM Corp., Armonk, NY, USA) statistical software package.
3. Results
The median age of the entire cohort was 70 yr (IQR: 63–77
yr). Men accounted for 73.4% (289 patients) and women for
26.6% (105 patients). The median values of preoperative
NLR, plasma fibrinogen, and CRP were 2.4, 364 mg/dl, and
0.25 mg/dl, respectively. Table 1 presents the clinicopatho-
logic parameters of the 394 patients. Patients with elevated
NLR tended to be older and had a higher incidence of
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positive LVI were significantly linked to elevation of
preoperative plasma fibrinogen, whereas CRP elevation
was significantly linked to positive LVI in our population.
Spearman rank correlations among continuous variables of
three markers were 0.320 for NLR and plasma fibrinogen
(p < 0.001), 0.304 for NLR and CRP (p < 0.001), and 0.548
for plasma fibrinogen and CRP (p < 0.001). We found a high
positive correlation between preoperative plasma fibrino-
gen and CRP levels, whereas the positive correlations among
preoperative NLR, plasma fibrinogen, and CRP levels were
only moderate.
During follow-up of the 394 patients, 113 (28.7%)
experienced disease recurrence and 82 (20.8%) died of
disease. Figure 1 shows the estimated probabilities of
recurrence-free and cancer-specific survival based on the
CMS. The risks of disease recurrence and cancer-specific
mortality rose along with an increase in CMS (p < 0.001 for
both). When none of the markers were elevated, recur-
rence-free and cancer-specific survival rates were 77.2% and
84.4%, respectively, at 3 yr. When all three markers were
elevated, recurrence-free and cancer-specific survival rates
decreased to 48.0% and 50.0%, respectively, at 3 yr. Table 2
shows associations of the CMS with clinicopathologic
variables. An increased CMS was significantly associated
with worse pathological features, such as advanced pT stageTable 2 – Association of baseline clinicopathologic characteristics and
radical nephroureterectomy
Cumulative marker score, n (%) 
Characteristic 0 (n = 203) 1 (n = 102) 2 (n = 52) 3 (n = 37
Age at RNU
70 yr 112 (55.2) 51 (50.0) 28 (53.8) 14 (37.8
>70 yr 91 (44.8) 51 (50.0) 24 (46.2) 23 (62.2
Sex
Male 149 (73.4) 78 (76.5) 36 (69.2) 26 (70.3
Female 54 (26.6) 24 (23.5) 16 (30.8) 11 (29.7
Tumor location
Renal pelvis 122 (60.1) 58 (56.9) 28 (53.8) 24 (64.9
Ureter 81 (39.9) 44 (43.1) 24 (46.2) 13 (35.1
Tumor grade
G1/2 75 (36.9) 35 (34.3) 8 (15.4) 10 (27.0
G3 128 (63.1) 67 (65.7) 44 (84.6) 27 (73.0
Pathologic T stage
pTa-1 81 (39.9) 21 (20.6) 12 (23.1) 11 (29.7
pT2 30 (14.8) 19 (18.6) 4 (7.7) 4 (10.8
pT3 88 (43.3) 62 (60.8) 33 (63.5) 18 (48.6
pT4 4 (2.0) 0 (0) 3 (5.8) 4 (10.8
Lymphovascular invasion
Negative 122 (60.1) 66 (64.7) 19 (36.5) 17 (45.9
Positive 81 (39.9) 36 (35.3) 33 (63.5) 20 (54.1
Concomitant carcinoma in situ
Negative 162 (79.8) 87 (85.3) 39 (75.0) 32 (86.5
Positive 41 (20.2) 15 (14.7) 13 (25.0) 5 (13.5
Lymph node involvement
pNx 186 (91.6) 94 (92.2) 47 (90.4) 30 (81.1
pN0 3 (1.5) 1 (1.0) 3 (5.8) 1 (2.7)
pN+ 14 (6.9) 7 (6.9) 2 (3.8) 6 (16.2
Adjuvant chemotherapy
No 165 (81.3) 79 (77.5) 35 (67.3) 27 (73.0
Yes 38 (18.7) 23 (22.5) 17 (32.7) 10 (27.0
RNU = radical nephroureterectomy.and positive LVI, whereas no significant difference was
found for age, sex, tumor location, and presence of CIS
among the four groups. In addition, patients in the two
elevated marker groups tended to have tumor grade 3
compared with patients with no or one elevated marker.
Univariate and multivariate analyses were performed to
determine the predictors of subsequent recurrence and
cancer-specific mortality following RNU. Multivariate
analyses that included all three markers separately
indicated that elevations of NLR, plasma fibrinogen, and
CRP levels were associated with both disease recurrence
(Table 3) and cancer-specific mortality (Table 4) following
RNU. When all three markers were included in one model,
only CRP elevation retained an independent association
with disease recurrence and cancer-specific mortality.
Moreover, multivariate analysis revealed that the CMS
was significantly associated with both disease recurrence
(Table 3) and cancer-specific mortality (Table 4) following
RNU. Addition of CMS to a standard multivariate model
improved predictive accuracy by 2.7% for disease recur-
rence and 3.9% for cancer-specific mortality, which were the
highest among our prognostic models.
A total of 102 subjects had died by the time of analysis.
The Kaplan-Meier curves in Supplementary Figure S1 show
an estimated probability of overall survival based on the
CMS, demonstrating that the risk of all-cause mortality rose number of cumulative marker score in 394 patients treated with
p value
) 0 vs 1 0 vs 2 0 vs 3 1 vs 2 1 vs 3 2 vs 3
)
) 0.393 0.864 0.052 0.652 0.204 0.136
)
) 0.562 0.548 0.694 0.333 0.457 0.916
)
) 0.588 0.414 0.585 0.721 0.397 0.299
)
) 0.652 0.003 0.246 0.013 0.417 0.178
)
)
)
) 0.002 0.015 0.033 0.032 0.003 0.546
)
) 0.435 0.002 0.109 0.001 0.046 0.373
)
) 0.243 0.449 0.342 0.117 0.859 0.184
)
) 0.937 0.145 0.140 0.166 0.176 0.114
)
) 0.430 0.029 0.245 0.175 0.583 0.567
Table 3 – Risk factors for predicting on disease recurrence following radical nephroureterectomy in 394 patients
Univariate analyses Multivariate analyses
Base model Base model
plus NLR
Base model plus
plasma ﬁbrinogen
Base model
plus serum CRP
Base model
plus CMS
HR (95% CI); p HR (95% CI); p HR (95% CI); p HR (95% CI); p HR (95% CI); p HR (95% CI); p
Age at RNU (>70 vs 70 yr) 1.13 (0.78–1.64); 0.513
Sex (male vs female) 1.46 (0.98–2.17); 0.060
Tumor location (renal pelvis vs ureter) 0.79 (0.53–1.15); 0.218
Tumor grade (G3 vs G1/2) 2.82 (1.72–4.61); <0.001
Pathologic T stage, p for trend <0.001 0.001 0.003 0.002 0.001 0.002
pT2 vs pTa/1 2.38 (0.99–5.73); 0.052 1.57 (0.63–3.87); 0.330 1.55 (0.63–3.81); 0.344 1.58 (0.64–3.93); 0.322 1.55 (0.63–3.85); 0.342 1.68 (0.67–4.19); 0.265
pT3/4 vs pTa/1 7.08 (3.69–13.6); <0.001 3.37 (1.62–7.01); 0.001 3.17 (1.51–6.66); 0.002 3.23 (1.54–6.76); 0.002 3.49 (1.66–7.34); 0.001 3.44 (1.61–7.35); 0.001
Lymphovascular invasion
(positive vs negative)
5.39 (3.51–8.28); <0.001 3.21 (1.98–5.20); <0.001 3.25 (1.99–5.29); <0.001 3.17 (1.95–5.16); <0.001 2.87 (1.74–4.71); < 0.001 2.97 (1.80–4.92); <0.001
Concomitant carcinoma in situ
(positive vs negative)
0.84 (0.52–1.35); 0.464
Adjuvant chemotherapy (yes vs no) 2.68 (1.84–3.90); <0.001
NLR (elevated vs not elevated) 1.66 (1.12–2.46); 0.011 – 1.49 (1.00–2.20); 0.049 – – –
Plasma ﬁbrinogen (elevated vs not elevated) 1.96 (1.35–2.84); <0.001 – – 1.69 (1.16–2.45); 0.006 – –
Serum CRP (elevated vs not elevated) 2.27 (1.55–3.33); <0.001 – – – 1.90 (1.29–2.80); 0.001 –
CMS, p for trend <0.001 0.001
1 vs 0 1.37 (0.86–2.19); 0.190 – – – – 1.23 (0.76–1.98); 0.404
2 vs 0 2.31 (1.39–3.83); 0.001 – – – – 1.60 (0.96–2.66); 0.073
3 vs 0 3.33 (1.92–5.77); <0.001 – – – – 3.11 (1.78–5.41); <0.001
Predictive accuracy, % – 75.4 76.7 77.2 77.4 78.1
Mantel-Haenszel test* – – 0.054 0.007 0.002 0.002
CI = conﬁdence interval; CMS = cumulative marker score; CRP = C-reactive protein; HR = hazard ratio; NLR = neutrophil-to-lymphocyte ratio; RNU = radical nephroureterectomy.
* Compared with base model.
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Table 4 – Risk factors for predicting on cancer-specific mortality following RNU in 394 patients
Univariate analyses Multivariate analyses
Base model Base model
plus NLR
Base model plus
plasma ﬁbrinogen
Base model
plus serum CRP
Base model
plus CMS
HR (95% CI); p HR (95% CI); p HR (95% CI); p HR (95% CI); p HR (95% CI); p HR (95% CI); p
Age at RNU (>70 vs 70 yr) 1.56 (1.01–2.41); 0.046
Sex (male vs female) 1.41 (0.89–2.25); 0.147
Tumor location (renal pelvis vs ureter) 0.91 (0.58–1.43); 0.695
Tumor grade (G3 vs G1/2) 3.26 (1.76–6.01); <0.001
Pathologic T stage, p for trend <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
pT2 vs pTa/1 2.52 (0.63–10.1); 0.191 1.85 (0.45–7.53); 0.393 1.81 (0.45–7.34); 0.408 1.90 (0.47–7.80); 0.371 1.82 (0.45–7.45); 0.403 2.21 (0.54–9.08); 0.274
pT3/4 vs pTa/1 13.5 (4.92–36.9); <0.001 7.70 (2.64–22.5); <0.001 7.25 (2.47–21.3); <0.001 7.40 (2.52–21.7); <0.001 8.35 (2.83–24.6); <0.001 8.83 (2.95–26.4); <0.001
Lymphovascular invasion
(positive vs negative)
5.12 (3.09–8.49); <0.001 2.44 (1.42–4.19); 0.001 2.42 (1.40–4.17); 0.002 2.41 (1.40–4.14); 0.002 2.06 (1.17–3.60); 0.012 2.06 (1.17–3.63); 0.012
Concomitant carcinoma in situ
(positive vs negative)
0.91 (0.53–1.58); 0.743
Adjuvant chemotherapy (yes vs no) 2.27 (1.45–3.55); <0.001
NLR (elevated vs not elevated) 2.01 (1.28–3.14); 0.002 – 1.71 (1.09–2.68); 0.019 – – –
Plasma ﬁbrinogen (elevated vs not elevated) 2.16 (1.40–3.34); <0.001 – – 1.85 (1.20–2.86); 0.006 – –
Serum CRP (elevated vs not elevated) 2.39 (1.53–3.73); <0.001 – – – 2.11 (1.34–3.33); 0.001 –
CMS, p for trend <0.001 <0.001
1 vs 0 1.41 (0.80–2.46); 0.236 – – – – 1.13 (0.64–2.00); 0.669
2 vs 0 2.14 (1.15–3.99); 0.017 – – – – 1.54 (0.82–2.89); 0.181
3 vs 0 4.42 (2.43–8.06); <0.001 – – – – 4.07 (2.22–7,49); <0.001
Predictive accuracy, % – 76.2 78.3 78.7 79.6 80.1
Mantel-Haenszel test* – – 0.022 0.006 0.002 <0.001
CI = conﬁdence interval; CMS = cumulative marker score; CRP = C-reactive protein; HR = hazard ratio; NLR = neutrophil-to-lymphocyte ratio; RNU = radical nephroureterectomy.
* Compared with base model.
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Table 5 – Risk factors for predicting on all-cause mortality following radical nephroureterectomy in 394 patients
Univariate analyses Multivariate analyses
Base model Base model
plus NLR
Base model plus
plasma ﬁbrinogen
Base model plus
serum CRP
Base model
plus CMS
HR (95% CI); p HR (95% CI); p HR (95% CI); p HR (95% CI); p HR (95% CI); p HR (95% CI); p
Age at RNU (>70 vs 70yr) 1.94 (1.28–2.83); 0.001 1.70 (1.14–2.52); 0.009 1.62 (1.09–2.41); 0.018 1.69 (1.14–2.51); 0.009 1.73 (1.16–2.57); 0.007 1.60 (1.07–2.38); 0.021
Sex (male vs female) 1.36 (0.89–2.08); 0.157
Tumor location (renal pelvis vs ureter) 0.83 (0.56–1.23); 0.359
Tumor grade (G3 vs G1/2) 2.30 (1.41–3.75); 0.001
Pathologic T stage, p for trend <0.001 0.001 0.002 0.001 <0.001 <0.001
pT2 vs pTa/1 2.56 (1.06–6.16); 0.036 2.06 (0.84–5.03); 0.115 1.95 (0.80–4.77); 0.141 2.11 (0.86–5.19); 0.102 2.04 (0.83–5.00); 0.119 2.44 (0.99–6.03); 0.054
pT3/4 vs pTa/1 6.05 (3.13–11.7); <0.001 3.85 (1.86–7.99); <0.001 3.60 (1.72–7.52); 0.001 3.72 (1.79–7.73); <0.001 4.20 (2.00–8.80); <0.001 4.53 (2.12–9.64); <0.001
Lymphovascular invasion
(positive vs negative)
3.53 (2.32–5.36); <0.001 1.96 (1.23–3.13); 0.005 1.96 (1.22–3.17); 0.006 1.95 (1.22–3.12); 0.006 1.66 (1.02–2.71); 0.042 1.67 (1.01–2.74); 0.044
Concomitant carcinoma in situ
(positive vs negative)
0.76 (0.45–1.28); 0.303
Adjuvant chemotherapy (yes vs no) 1.78 (1.18–2.70); 0.006
NLR (elevated vs not elevated) 2.09 (1.40–3.12); <0.001 – 1.77 (1.18–2.66); 0.006 – – –
Plasma ﬁbrinogen (elevated vs not elevated) 1.88 (1.27–2.79); 0.002 – – 1.66 (1.12–2.46); 0.011 – –
Serum CRP (elevated vs not elevated) 2.33 (1.56–3.48); <0.001 – – – 2.13 (1.41–3.21); <0.001 –
CMS, p for trend <0.001 <0.001
1 vs 0 1.20 (0.72–2.00); 0.477 – – – – 0.99 (0.59–1.65); 0.959
2 vs 0 1.92 (1.10–3.36); 0.022 – – – – 1.46 (0.83–2.57); 0.192
3 vs 0 4.18 (2.46–7.13); <0.001 – – – – 3.80 (2.22–6.52); <0.001
Predictive accuracy, % – 73.0 75.1 74.3 75.5 77.0
Mantel-Haenszel test* – – 0.007 0.012 0.001 <0.001
CI = conﬁdence interval; CMS = cumulative marker score; CRP = C-reactive protein; HR = hazard ratio; NLR = neutrophil-to-lymphocyte ratio; RNU = radical nephroureterectomy.
* Compared with base model.
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performed univariate and multivariate analyses to deter-
mine the predictors of all-cause mortality (Table 5).
Multivariate analyses that included all three markers
separately indicated that elevations of NLR, plasma
fibrinogen, and CRP levels were associated with worse
all-cause mortality following RNU. Similarly, only CRP
elevation was independently associated with all-cause
mortality when all three markers were included in
one model. Furthermore, multivariate analysis revealed
that the CMS was significantly associated with worse all-
cause mortality following RNU. The addition of CMS to a
standard multivariate model improved the predictive
accuracy by 4.0% for all-cause mortality, which was the
highest among our prognostic models.
4. Discussion
We retrospectively reviewed a multi-institutional cohort
of 394 patients who underwent RNU and analyzed the
impact of CMS on subsequent outcomes. In our setting,
although multivariate analyses showed that the use of each
inflammatory marker alone was as predictive as clinico-
pathologic indices for prognosis, combinations like CMS
provided more accurate prediction of disease recurrence
and cancer-specific and all-cause mortality following RNU.
Increasing evidence has suggested a significant inverse
association between systemic inflammatory markers and
patient survival with malignancies. Many investigators have
documented the prognostic value of systemic inflammatory
markers and then included those in their risk models. In
addition, guidelines (eg, for renal cell carcinoma) refer to the
elevation of systemic inflammatory markers as a significant
prognostic tool [21]. Among blood-based biomarkers, we and
others examined the efficacy of preoperative NLR, plasma
fibrinogen, and serum CRP, suggesting that all of these
markers are associated with disease recurrence and mortality
in UTUC following RNU [7–12]. However, because of the lack
of data concerning the relationship or interaction between
elevations of each inflammatory marker, we do not yet have a
sufficient understanding of the proper use of these indices.
In the present study, we found a significant positive
correlation among all three markers, especially among the
preoperative levels of plasma fibrinogen and serum CRP.
We then confirmed our hypothesis, suggesting that
combinations of the three markers could be more predic-
tive for prognosis than a single marker, and further found
the superiority of CMS rather than combinations of two
(ie, NLR and plasma fibrinogen, NLR and serum CRP, or
plasma fibrinogen and serum CRP) of the three markers
(Supplementary Table S1–3).
Superior predictive value for prognosis has been achieved
by assessment using combinations rather than single
markers of cell cycle regulators and apoptosis markers
[20,22–25]. Using immunostaining including p53, p21, and
p27 expression, Shariat et al reported that an increased
number of altered cell cycle regulators was independently
associated with the risk of disease progression and mortality
in bladder UC patients [22,23]. Such results were furtherconfirmed by prospective analyses in UTUC [25]. Karam
et al reported an assessment of an altered number of
apoptosis markers, Bcl-2, caspase-3, p53, and survivin
expression, resulting in a significant increase in the accuracy
of survival prediction following radical cystectomy [20].
In addition, combined use of promoter methylation status
in tumors or urine would be an innovative approach in the
management of both bladder UC and UTUC [26,27].
Although such molecules improve the prediction of
survival for UTUC, we propose that our prognostic models
may be useful for two different reasons. First, all three
markers in the present study can be clinically applied for
routine measurement because of their low cost and easy
accessibility. Second, these three markers can be available
before surgical intervention, such as RNU. Indeed, neoad-
juvant chemotherapy has the advantage of more effective
delivery of chemotherapy due to better renal function in
UTUC patients [28,29]. Extended lymph node dissection at
RNU may have therapeutic potential to improve disease
outcomes [1,30]. Despite appropriate patient selection for
the latter two strategies potentially being challenging for
physicians prior to RNU [6,28], the results may assist in
decision making when considering the need for these
modalities in some situations.
Our study has several limitations. It is limited by its
retrospective nature, by the heterogeneous group of
patients due to a multi-institutional study design, by short
median follow-up, and by lack of a central pathology review
of RNU specimens. In addition, laboratory assays were
performed at each institution; however, when we reran the
data set by including the data for the treating institution,
the statistical significance of the variables did not change.
Patients with potent infectious diseases such as urinary
tract infections without fever may be included. Not all
patients underwent regional or extended lymph node
dissection, which may have potentially influenced subse-
quent metastatic spread. A wide variety of adjuvant
chemotherapies were administered at the attending phy-
sician’s discretion; however, of 88 patients with adjuvant
chemotherapy, 76 (86.4%) were administered cisplatin-
based regimens, with the MVAC regimen for most.
Furthermore, the present data do not include information
on surgical margins in RNU specimens, which may improve
the prediction of subsequent outcome. External validation
of the present models is warranted, for example, in a future
prospective study.
5. Conclusions
This retrospective study showed that a CMS defined by
preoperative NLR, plasma fibrinogen, and serum CRP was
an independent predictor of patient survival following
RNU. Although the use of each blood-based inflammatory
marker alone provides additional prognostic information,
the addition of the CMS to multivariate analysis can be
most predictive among the present models. These data
confirm our hypothesis and suggest the potent impact of
the CMS as a novel predictive tool for prognosis in UTUC
patients.
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